image
Healthcare - Medical - Devices - NYSE - IE
$ 87.53
1.78 %
$ 112 B
Market Cap
29.47
P/E
1. INTRINSIC VALUE

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease.[ Read More ]

The intrinsic value of one MDT stock under the base case scenario is HIDDEN Compared to the current market price of 87.5 USD, Medtronic plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart MDT

image
FINANCIALS
32.4 B REVENUE
3.64%
5.14 B OPERATING INCOME
-6.22%
3.68 B NET INCOME
-2.85%
6.79 B OPERATING CASH FLOW
12.39%
-2.37 B INVESTING CASH FLOW
32.26%
-4.45 B FINANCING CASH FLOW
10.28%
7.92 B REVENUE
-7.85%
1.28 B OPERATING INCOME
-16.31%
1.04 B NET INCOME
59.33%
986 M OPERATING CASH FLOW
-64.49%
-259 M INVESTING CASH FLOW
62.79%
-731 M FINANCING CASH FLOW
69.01%
Balance Sheet Decomposition Medtronic plc
image
Current Assets 21.9 B
Cash & Short-Term Investments 8 B
Receivables 6.13 B
Other Current Assets 7.8 B
Non-Current Assets 68 B
Long-Term Investments 1.62 B
PP&E 7.14 B
Other Non-Current Assets 59.3 B
Current Liabilities 10.8 B
Accounts Payable 2.41 B
Short-Term Debt 1.28 B
Other Current Liabilities 7.1 B
Non-Current Liabilities 28.8 B
Long-Term Debt 24.8 B
Other Non-Current Liabilities 4 B
EFFICIENCY
Earnings Waterfall Medtronic plc
image
Revenue 32.4 B
Cost Of Revenue 12.9 B
Gross Profit 19.5 B
Operating Expenses 16.1 B
Operating Income 5.14 B
Other Expenses 1.47 B
Net Income 3.68 B
RATIOS
60.11% GROSS MARGIN
60.11%
15.89% OPERATING MARGIN
15.89%
11.36% NET MARGIN
11.36%
7.32% ROE
7.32%
4.09% ROA
4.09%
5.24% ROIC
5.24%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Medtronic plc
image
Net Income 3.68 B
Depreciation & Amortization 2.65 B
Capital Expenditures -1.59 B
Stock-Based Compensation 393 M
Change in Working Capital -484 M
Others 718 M
Free Cash Flow 5.2 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Medtronic plc
image
Wall Street analysts predict an average 1-year price target for MDT of $95.1 , with forecasts ranging from a low of $82 to a high of $106 .
MDT Lowest Price Target Wall Street Target
82 USD -6.32%
MDT Average Price Target Wall Street Target
95.1 USD 8.61%
MDT Highest Price Target Wall Street Target
106 USD 21.10%
4. DIVIDEND ANALYSIS
0.88% DIVIDEND YIELD
0.7 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Medtronic plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.6 M USD 1
6-9 MONTHS
2.68 M USD 2
9-12 MONTHS
411 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
5 months ago
Jun 07, 2024
Sell 1.47 M USD
Martha Geoffrey
Chairman and CEO
- 17519
83.76 USD
5 months ago
Jun 07, 2024
Sell 134 K USD
Martha Geoffrey
Chairman and CEO
- 1594
83.82 USD
7 months ago
Apr 08, 2024
Sell 71 K USD
Marinaro Michael
EVP & President, Surgical OU
- 854
83.14 USD
8 months ago
Feb 21, 2024
Sell 136 K USD
Salmon Sean
EVP & President Cardiovascular
- 1594
85.06 USD
8 months ago
Feb 21, 2024
Sell 1.11 M USD
Salmon Sean
EVP & President Cardiovascular
- 13066
85.15 USD
8 months ago
Feb 21, 2024
Sell 1.36 M USD
Salmon Sean
EVP & President Cardiovascular
- 16035
85.12 USD
10 months ago
Dec 19, 2023
Sell 411 K USD
Wall Brett A.
EVP & Pres Neuroscience
- 4997
82.17 USD
1 year ago
Aug 23, 2023
Sell 838 K USD
Smith Gregory L
EVP Global Ops & Supply Chain
- 10000
83.84 USD
1 year ago
Aug 14, 2023
Sell 83.4 K USD
Wall Brett A.
EVP & Pres Neuroscience
- 1000
83.38 USD
1 year ago
Aug 04, 2023
Sell 114 K USD
Marinaro Michael
EVP & President, Surgical OU
- 1352
84.11 USD
1 year ago
Jul 14, 2023
Sell 176 K USD
Wall Brett A.
EVP & Pres Neuroscience
- 2000
87.97 USD
1 year ago
Jul 10, 2023
Sell 157 K USD
TEN HOEDT ROB
EVP and Pres. Global Regions
- 1808
86.59 USD
1 year ago
Jul 10, 2023
Sell 321 K USD
TEN HOEDT ROB
EVP and Pres. Global Regions
- 3706
86.58 USD
1 year ago
Dec 13, 2022
Sell 1.34 M USD
Salmon Sean
EVP & President Cardiovascular
- 16631
80.4964 USD
2 years ago
Oct 14, 2022
Sell 196 K USD
TEN HOEDT ROB
EVP and Pres. Global Regions
- 2404
81.537 USD
2 years ago
Mar 18, 2022
Sell 75 K USD
PARKHILL KAREN L
EVP & Chief Financial Officer
- 682
110 USD
2 years ago
Mar 11, 2022
Sell 632 K USD
Surface Carol A
SVP, Chief HR Officer
- 6000
105.3 USD
2 years ago
Dec 23, 2021
Sell 737 K USD
WHITE ROBERT JOHN
EVP & Pres. Medical Surgical
- 7218
102.04 USD
2 years ago
Dec 16, 2021
Bought 517 K USD
ANDERSON RICHARD H
Director
+ 5010
103.26 USD
2 years ago
Dec 06, 2021
Sell 75 K USD
PARKHILL KAREN L
EVP & Chief Financial Officer
- 682
110 USD
3 years ago
Sep 30, 2021
Sell 6.22 M USD
Lerman Bradley E
SVP General Counsel & Corp Sec
- 49147
126.58 USD
3 years ago
Aug 31, 2021
Sell 6.81 M USD
Lerman Bradley E
SVP General Counsel & Corp Sec
- 50775
134.17 USD
3 years ago
Aug 25, 2021
Sell 978 K USD
Salmon Sean
EVP & Pres Diabetes/Cardiovasc
- 7290
134.09 USD
3 years ago
Aug 25, 2021
Sell 2.83 M USD
Salmon Sean
EVP & Pres Diabetes/Cardiovasc
- 21129
134.08 USD
3 years ago
Aug 25, 2021
Sell 1.34 M USD
Martha Geoffrey
CEO
- 10100
132.67 USD
3 years ago
Aug 02, 2021
Sell 526 K USD
Lerman Bradley E
SVP General Counsel & Corp Sec
- 4000
131.52 USD
3 years ago
Jun 28, 2021
Sell 1.44 M USD
Martha Geoffrey
CEO
- 11500
125.29 USD
3 years ago
Jun 21, 2021
Sell 14.2 K USD
Wall Brett A.
EVP & Pres Neuroscience
- 115
123.5 USD
3 years ago
Jun 15, 2021
Sell 75.3 K USD
PARKHILL KAREN L
EVP & Chief Financial Officer
- 605
124.47 USD
3 years ago
Jun 01, 2021
Sell 317 K USD
Wall Brett A.
EVP & Pres Neuroscience
- 2473
128.07 USD
3 years ago
May 28, 2021
Sell 4.39 M USD
Liddicoat John R
EVP & President of Americas
- 34656
126.65 USD
3 years ago
Apr 05, 2021
Sell 1.11 M USD
Martha Geoffrey
CEO
- 9308
118.83 USD
3 years ago
Mar 15, 2021
Sell 75.3 K USD
PARKHILL KAREN L
EVP & Chief Financial Officer
- 632
119.12 USD
3 years ago
Mar 02, 2021
Sell 846 K USD
TEN HOEDT ROB
EVP & President EMEA
- 7168
117.98 USD
3 years ago
Dec 28, 2020
Sell 1.72 M USD
Surface Carol A
SVP, Chief HR Officer
- 15000
114.9 USD
3 years ago
Dec 22, 2020
Sell 301 K USD
Lerman Bradley E
SVP General Counsel & Corp Sec
- 2605
115.56 USD
3 years ago
Dec 18, 2020
Sell 1.26 M USD
WHITE ROBERT JOHN
EVP & Pres. Medical Surgical
- 10930
115.46 USD
3 years ago
Dec 15, 2020
Sell 76.6 K USD
PARKHILL KAREN L
EVP & Chief Financial Officer
- 670
114.33 USD
4 years ago
Nov 09, 2020
Sell 2.34 M USD
Lerman Bradley E
SVP General Counsel & Corp Sec
- 20715
113.13 USD
4 years ago
Oct 09, 2020
Sell 82.7 K USD
ISHRAK OMAR
Executive Chairman
- 763
108.4 USD
4 years ago
Oct 08, 2020
Sell 87.7 K USD
Lerman Bradley E
SVP General Counsel & Corp Sec
- 797
110 USD
4 years ago
Oct 08, 2020
Bought 500 K USD
ANDERSON RICHARD H
Director
+ 4607
108.52 USD
4 years ago
Sep 23, 2020
Sell 1 M USD
TEN HOEDT ROB
EVP & President EMEA
- 9584
104.34 USD
4 years ago
Sep 15, 2020
Sell 75.7 K USD
PARKHILL KAREN L
EVP & Chief Financial Officer
- 702
107.78 USD
4 years ago
Sep 09, 2020
Sell 1 M USD
TEN HOEDT ROB
EVP & President EMEA
- 9563
105.05 USD
4 years ago
May 29, 2020
Sell 195 K USD
Surface Carol A
SVP, Chief HR Officer
- 2000
97.72 USD
4 years ago
Feb 20, 2020
Bought 997 K USD
ISHRAK OMAR
Chairman & CEO
+ 8771
113.68 USD
7. News
Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know The latest trading day saw Medtronic (MDT) settling at $87.53, representing a +1.78% change from its previous close. zacks.com - 1 day ago
Insights Into Medtronic (MDT) Q2: Wall Street Projections for Key Metrics Besides Wall Street's top -and-bottom-line estimates for Medtronic (MDT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended October 2024. zacks.com - 2 days ago
Beverly Hills surgeon sues Medtronic for patent infringement A Beverly Hills surgeon is suing Medtronic claiming patent infringement of her hernia repair mesh product. It's the latest in a series of patent challenges against Medtronic. cnbc.com - 3 days ago
The Zacks Analyst Blog Oracle, Micron Technology, Medtronic and The Cato Oracle, Micron Technology, Medtronic and The Cato are included in this Analyst Blog. zacks.com - 5 days ago
Medtronic (MDT) Stock Sinks As Market Gains: Here's Why The latest trading day saw Medtronic (MDT) settling at $87.72, representing a -0.45% change from its previous close. zacks.com - 1 week ago
Ping An Health and Medtronic Form Strategic Partnership at the China International Import Expo (CIIE) HONG KONG and SHANGHAI , Nov. 7, 2024 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) established a strategic partnership with Medtronic (Shanghai) Management Co., Ltd. ("Medtronic") at the 7th China International Import Expo (CIIE) held at the National Exhibition and Convention Center (Shanghai) on 6 November, 2024. prnewswire.com - 1 week ago
Medtronic Stock Trading at a Discount Before Q2 Earnings: Time to Buy? Like its peers, the impact of the present geopolitical situation may have curbed fiscal second-quarter profits for Medtronic. zacks.com - 1 week ago
Medtronic to announce financial results for its second quarter of fiscal year 2025 GALWAY, Ireland , Nov. 5, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2025 on Tuesday, November 19, 2024. A news release will be issued at approximately 5:45 a.m. prnewswire.com - 1 week ago
2 Dividend Stocks to Buy for a Lifetime of Passive Income These are the kinds of stocks that can allow investors to sleep easy at night. fool.com - 2 weeks ago
Medtronic (MDT) Outperforms Broader Market: What You Need to Know Medtronic (MDT) reachead $90.07 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close. zacks.com - 2 weeks ago
CMS grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral™ renal denervation catheter The Symplicity ™ blood pressure procedure offers patients a new adjunct approach to lowering blood pressure  GALWAY, Ireland , Nov. 1, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral™ renal denervation (RDN) catheter, used in the Symplicity™ blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System. TPT payment, which will be effective for up to three years beginning January 1, 2025, aims to support patient access to new and innovative technology, including devices granted Breakthrough Device Designations like the Symplicity Spyral RDN system. prnewswire.com - 2 weeks ago
Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock Medtronic announces new long-term favorable data for its Symplicity Spyral RDN system, which has undergone a SPYRAL HTN-ON MED clinical trial. zacks.com - 2 weeks ago
8. Profile Summary

Medtronic plc MDT

image
COUNTRY IE
INDUSTRY Medical - Devices
MARKET CAP $ 112 B
Dividend Yield 0.88%
Description Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Contact 20 On Hatch, Dublin, 2 https://www.medtronic.com
IPO Date May 2, 1973
Employees 95000
Officers Ms. Jennifer M. Kirk Senior Vice President, Global Controller & Chief Accounting Officer Dr. Kenneth E. Washington Ph.D. Senior Vice President and Chief Technology & Innovation Officer Mr. Ryan Weispfenning Vice President & Head of Investor Relations Mr. Brett A. Wall Executive Vice President & President of Neuroscience Portfolio Dr. Laura Mauri M.D., M.Sc. Senior Vice President and Chief Scientific & Medical Officer Mr. Gregory L. Smith Executive Vice President of Global Operations & Supply Chain Gary Corona Senior Vice President of Global Financial Planning and Analysis & Interim Chief Financial Officer Mr. Mark Ploof Senior Vice President of Global Operations and Business Services Mr. Geoffrey Straub Martha Chairman of the Board & Chief Executive Officer Mr. Sean M. Salmon Executive Vice President & President of Cardiovascular Portfolio